Condition: Childhood ALL · Sponsor: French Africa Pediatric Oncology Group
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
This description comes directly from the study's public registry record.
Ndella Ms DIOUF, MD · 00(221)77 656 49 13. · ndella.diouf@gfaop.org
BRENDA Ms MALLON, MSc · 0033142115411 · brenda.mallon@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| CHU de Treichville à ABIDJAN | Abidjan, Côte d’Ivoire | Recruiting |
| CHU Donka 030 BP 554 | Conakry, Guinea | Recruiting |
| Hôpital Aristide Le Dantec, Avenue Pasteur, | Dakar, Senegal | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04794296